Tenax Therapeutics (TENX) Long-Term Debt Issuances (2011 - 2024)
Tenax Therapeutics (TENX) reported Long-Term Debt Issuances of $279000.0 for Q3 2024, up 62.89% on a YoY basis from $171283.0 in Q4 2023, and up 108.21% sequentially from $134000.0 in Q2 2024.
Tenax Therapeutics (TENX) Long-Term Debt Issuances (2011 - 2024) Analysis & Trends
Tenax Therapeutics (TENX) has 8 years of Long-Term Debt Issuances data on file, last reported at $279000.0 in Q3 2024.
- For the quarter ending Q3 2024, Long-Term Debt Issuances rose 62.89% year-over-year to $279000.0; the trailing twelve-month figure through Jun 2025 stood at $279000.0 (down 50.83% YoY), and the FY2024 full-year result was $501000.0, down 19.71% from the prior year.
- Long-Term Debt Issuances advanced to $279000.0 in Q3 2024, from $134000.0 in the prior quarter.
- In the past five years, Long-Term Debt Issuances ranged from a high of $364546.0 in Q1 2022 to a low of -$364546.0 in Q4 2022.
- A 3-year average of $102272.7 and a median of $134000.0 in 2024 frame the typical range for Long-Term Debt Issuances.
- Peak annual rise in Long-Term Debt Issuances reached 283.03% in 2023, while the deepest fall reached 69.72% in 2023.
- Tracing TENX's Long-Term Debt Issuances over 3 years: stood at -$364546.0 in 2022, then soared by 147.78% to $174164.0 in 2023, then surged by 60.19% to $279000.0 in 2024.
- Business Quant data shows TENX's Long-Term Debt Issuances at $279000.0 in Q3 2024, $134000.0 in Q2 2024, and $88000.0 in Q1 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Long-Term Debt Issuances (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | - |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | - |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | - |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | Tenax Therapeutics | 67,856.40 | 67,856.40 | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2024 | 279,000.00 |
| Sep 30, 2024 | 279,000.00 |
| Jun 30, 2024 | 134,000.00 |
| Jun 30, 2024 | 134,000.00 |
| Mar 31, 2024 | 88,000.00 |
| Mar 31, 2024 | 88,000.00 |
| Dec 31, 2023 | 174,164.00 |
| Dec 31, 2023 | 174,164.00 |
| Sep 30, 2023 | 171,283.00 |
| Sep 30, 2023 | 171,283.00 |
| Jun 30, 2023 | 168,157.00 |
| Jun 30, 2023 | 168,157.00 |
| Mar 31, 2023 | 110,396.00 |
| Mar 31, 2023 | 110,396.00 |
| Dec 31, 2022 | -364,546.00 |
| Dec 31, 2022 | -364,546.00 |
| Sep 30, 2022 | 91,875.00 |
| Sep 30, 2022 | 91,875.00 |
| Jun 30, 2022 | -91,875.00 |
| Jun 30, 2022 | -91,875.00 |